Acrux and its partner Padagis announced the launch of an AB-rated generic version of Emla® Cream in the United States. Emla® (prilocaine 2.5% and lidocaine 2.5%) Cream is indicated as a topical anaesthetic for use on: normal intact skin for local analgesia; and genital mucous membranes for superficial minor surgery and as pre-treatment for infiltration anaesthesia.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.061 AUD | +1.67% | +1.67% | +38.64% |
Apr. 03 | Acrux, TruPharma Launch Dapsone 5% Gel in US | MT |
Feb. 29 | Transcript : Acrux Limited, H1 2024 Earnings Call, Feb 29, 2024 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+38.64% | 11.38M | |
+20.81% | 43.34B | |
+20.44% | 21.96B | |
+12.12% | 14.09B | |
+12.97% | 13.64B | |
+39.74% | 11.43B | |
-8.59% | 6.86B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+8.46% | 5.22B |
- Stock Market
- Equities
- ACR Stock
- News Acrux Limited
- Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States